Compare · AZN vs ITRM
AZN vs ITRM
Side-by-side comparison of AstraZeneca PLC (AZN) and Iterum Therapeutics plc (ITRM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ITRM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $270.37B.
- AZN has hit the wire 23 times in the past 4 weeks while ITRM has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 2 for ITRM).
- Company
- AstraZeneca PLC
- Iterum Therapeutics plc
- Price
- -
- -
- Market cap
- $270.37B
- -
- 1M return
- +1.07%
- -
- 1Y return
- +91.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2018
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 2
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Iterum Therapeutics plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Latest AZN
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Latest ITRM
- Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Iterum Therapeutics Announces Filing of Winding Up Petition
- Iterum Therapeutics plc filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Iterum Therapeutics plc filed SEC Form 8-K: Other Events
- Iterum Therapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Iterum Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- SEC Form DEFA14A filed by Iterum Therapeutics plc
- Iterum Therapeutics Provides Business Update
- SEC Form DEFA14A filed by Iterum Therapeutics plc
- SEC Form DEF 14A filed by Iterum Therapeutics plc